HOME > Investors > Press Releases
Subject ViroMed to Present at Biotech Japan 2017 Keynote Session
Writer ViroMed
Date 2017/06/30

ViroMed to Present at Biotech Japan 2017 Keynote Session
VM202’s Potential to Become First in class & Best in class in Advanced Markets

 

ViroMed is presenting novel drug development cases, including the results from its clinical trials of VM202-DPN and VM202-PAD, at a Keynote session of one of the biggest and most comprehensive biopharma events in Asia, Biotech Japan 2017 taking place on Jun 28-30 at the Tokyo Big Sight.

VM202 is an innovative medicine under development targeting diabetic peripheral neuropathy (DPN) and diabetic/ischemic chronic non-healing foot ulcer (NHU), whose phase III clinical trials are underway in the US. Basically, VM202 is plasmid DNA containing hepatocyte growth factor (HGF), which can be delivered through intramuscular injection to induce formation of new blood vessels and regeneration of damaged nerve cells.

As the only plasmid DNA undergoing phase III clinical trial targeting DPN in the US, its safety and efficacy profile as well as neuroregenerative potential have been confirmed through the phase I and phase II trials. VM202 has been shown to downregulate the expression levels of pain related genes in the spinal cord and the dorsal root ganglion (DRG) as well as to induce remyelination, whose mechanism demonstrates a potential to become Disease Modifying Drug, a drug that treats not only symptoms but also fundamental causes.

Clinical research of plasmid DNA using an angiogenic growth factor has been carried out since the late 1990s. AnGes MG, a Japanese company, has recently announced that it would apply for an approval on HGF plasmid (Beperminogene perplasmid) in the Japanese market targeting critical limb ischemia (CLI), signaling commercialization of plasmid DNA medicine. 

ViroMed successfully completed phase I and phase II clinical trials of VM202 targeting CLI in the US, and its ongoing phase III is targeting chronic non-healing ulcer (NHU), which is a pre-stage condition before CLI and has about 3-4 times more patients globally than CLI, securing market opportunity that is more expandable than that of AnGes MG.

Considering the excellence of substance, its developmental status, and the size of potential market as well as its expandability, VM202 is well expected to become a First-in-Class and Best-in-Class medicine in advanced markets.

In addition to its research on gene therapy, ViroMed is presenting the results of its research and development on phytotherapeutics while participating in the start-up poster booths to promote its phytotherapeutic products.   

------------------------------------

 [More information]

Biotech Japan 2017

One of the biggest and most comprehensive biopharma events in Asia held at the Tokyo Big Sight on Jun 28-30.

ViroMed will be part of,

(1) Keynote Session 
    - Dr. Sunyoung Kim, CSO, Guest speaker
    - Subject: Development of Innovative Drugs Using Plasmid DNA

                  - Case of Diabetic Peripheral Neuropathy (DPN)

    ​- Date: Jun 28, 12:30 - 14:30
    -
http://www.bio-t.jp/en/Conference/Program/ 
 

(2) Start-up presentation / Phytotherapeutics research: Jun 28, 15:50 - 16:20

(3) Exhibition booth / Start-up poster: Jun 28-30 (3 days)